NEW YORK (GenomeWeb News) – BG Medicine has tapped Paul Sohmer to be president, CEO, and a member of its board of directors, effective immediately, the company said this week.

Sohmer previously was CEO of several medical device and diagnostics companies, including Pathway Diagnostics, Viracor-IBT Laboratories, and Orthocon, and he was chairman, president, and CEO of TriPath Imaging before it was acquired by Becton Dickinson.

Early in his career, Sohmer also was CEO of Genetrix, a genetic testing lab that was acquired by Genzyme.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.